Skip to content
THE MARKET IS OPEN. COMMON SENSE REMAINS THINLY TRADED.
THE ARCHIVES

Category: Witty or Risky?

Medtronic stock analysis
March 16, 2026 · 8 MIN READ

Medtronic Stock Analysis: Is MDT Witty or Risky in 2026?

At-a-Glance: Medtronic (MDT) 2026 Fundamentals Metric Q3 2026 Status The Witty Take Current Price ~$87.38 Trading at a 6-8% intrinsic discount Price Target $110.00 ~22.8% potential upside Q3 2026 Revenue $9.02 Billion Beat consensus estimates; 6% organic growth Dividend Yield ~3.26% ($0.71/qtr) Reliable passive income generator Key Catalyst 1 Pulsed Field Ablation PFA sales grew…

Inspect the Evidence →
Industrial pollution factory at dusk with dark smoke, oil refinery, environmental impact, industrial investment concepts.
October 31, 2025 · 14 MIN READ

Pumping Profits or Refining Your Portfolio Into Dust? The Unvarnished Truth About Valero Stock

Pumping Profits or Refining Your Portfolio Into Dust? The Unvarnished Truth About Valero Stock Let’s talk about Valero stock (NYSE: VLO), shall we? Because nothing screams “sexy investment opportunity” quite like America’s largest independent petroleum refiner. I know, I know—you were probably hoping for another article about some flashy tech startup that promises to disrupt…

Inspect the Evidence →
Air-products-stock-market-investing-industrial-stock-photo.
October 30, 2025 · 12 MIN READ

Air Products (APD): The Boring Stock That’s Quietly Printing Money

Air Products Stock: The Boring Industrial Giant Quietly Building a $15 Billion Hydrogen Empire Last Updated: October 29, 2025 | Ticker: APD | Dividend Yield: 2.5% Nobody gets excited about industrial gases. Oxygen, nitrogen, hydrogen—these are commodities that power refineries, semiconductor fabs, and steel mills. They’re invisible, essential, and completely unsexy. Which is exactly why…

Inspect the Evidence →
ABBVIE stock of the week, dividend stock analysis, Humira survival, biotech investment, dividend income.
October 29, 2025 · 9 MIN READ

AbbVie (ABBV): Is This Dividend Tank Built to Survive After Humira?

AbbVie (ABBV): Is This Dividend Tank Built to Survive After Humira? AbbVie’s been called a one-drug wonder for years — and that drug, Humira, is finally fading into retirement. But before you start writing AbbVie’s obituary, take a look at the company’s replacement lineup. Between Skyrizi and Rinvoq, this “dividend tank” might just have enough…

Inspect the Evidence →
Nvidia logo outside corporate building promoting investment opportunities and stock trading.
September 5, 2025 · 9 MIN READ

Nvidia in 2025: Explosive Rocket Ship or Dangerous Bubble About to Pop?

Let’s be honest – Nvidia has become more than just a stock. It’s practically a religion at this point, complete with devoted followers on financial Twitter and skeptics warning of impending doom. With a market cap flirting around $3.1 trillion as of September 2025, it’s worth more than most countries’ entire economies. The question everyone’s…

Inspect the Evidence →
Alphabet vs Tesla earnings debate with guitar and explosive graphics, illustrating stock market rivalry.
July 23, 2025 · 5 MIN READ

Alphabet vs. Tesla Earnings: Who’s the Real Market Rockstar?

It’s that magical time of the quarter when CEOs sweat, analysts pretend to know the future, and investors hover over their “Buy” or “Sell” buttons like they’re defusing a bomb. Yep, earnings season is back, and the spotlight is on two of the market’s biggest attention hogs: Tesla (TSLA) and Alphabet (GOOGL). If you’ve ever…

Inspect the Evidence →